Market Cap ₹3713 Cr.
Stock P/E 33.8
P/B 4.4
Current Price ₹432.5
Book Value ₹ 97.4
Face Value 10
52W High ₹503.9
Dividend Yield 0%
52W Low ₹ 304
Yatharth Hospital & Trauma Care Services Ltd is a reputable medical institution dedicated to providing comprehensive healthcare solutions. With a focus on excellence, the company offers a wide range of medical services, including emergency trauma care, advanced surgical procedures, diagnostic imaging, and specialized medical consultations. Yatharth Hospital is renowned for its state-of-the-art facilities, cutting-edge technology, and a team of experienced medical professionals who prioritize patient well-being. The hospital is committed to delivering high-quality and compassionate medical care to individuals of all ages. Yatharth Hospital & Trauma Care Services Ltd stands as a beacon of health and healing, striving to enhance the overall health and quality of life for its patients.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|
| Net Sales | 111 | 128 | 138 | 155 | 171 | 167 |
| Other Income | 1 | 1 | 1 | 1 | 4 | 5 |
| Total Income | 112 | 129 | 138 | 155 | 175 | 172 |
| Total Expenditure | 85 | 94 | 101 | 113 | 126 | 120 |
| Operating Profit | 26 | 34 | 37 | 42 | 49 | 52 |
| Interest | 4 | 5 | 6 | 6 | 3 | 0 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 16 | 23 | 24 | 29 | 40 | 44 |
| Provision for Tax | 5 | 7 | 3 | 10 | 12 | 14 |
| Profit After Tax | 11 | 16 | 21 | 19 | 28 | 29 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 11 | 16 | 21 | 19 | 28 | 29 |
| Adjusted Earnings Per Share | 1.7 | 2.5 | 3.2 | 2.9 | 3.2 | 3.4 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 102 | 146 | 229 | 401 | 520 | 631 |
| Other Income | 0 | 0 | 1 | 2 | 3 | 11 |
| Total Income | 102 | 146 | 229 | 403 | 523 | 640 |
| Total Expenditure | 82 | 108 | 161 | 289 | 385 | 460 |
| Operating Profit | 20 | 39 | 69 | 114 | 138 | 180 |
| Interest | 7 | 20 | 20 | 23 | 23 | 15 |
| Depreciation | 8 | 21 | 21 | 28 | 28 | 29 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 5 | -2 | 28 | 63 | 88 | 137 |
| Provision for Tax | 1 | -0 | 9 | 19 | 22 | 39 |
| Profit After Tax | 4 | -2 | 20 | 44 | 66 | 97 |
| Adjustments | -0 | 1 | -1 | 0 | 0 | 0 |
| Profit After Adjustments | 4 | -1 | 18 | 44 | 66 | 97 |
| Adjusted Earnings Per Share | 0.6 | -0.2 | 2.8 | 6.7 | 10 | 12.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | 53% | 0% | 0% |
| Operating Profit CAGR | 21% | 52% | 0% | 0% |
| PAT CAGR | 50% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 44% | 40% | 25% | 25% |
| ROCE Average | 27% | 24% | 17% | 17% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Shareholder's Funds | 56 | 54 | 72 | 117 | 183 |
| Minority's Interest | 3 | 8 | 8 | 0 | 0 |
| Borrowings | 146 | 157 | 164 | 207 | 201 |
| Other Non-Current Liabilities | 10 | 8 | 9 | -1 | -5 |
| Total Current Liabilities | 42 | 60 | 55 | 97 | 100 |
| Total Liabilities | 257 | 287 | 309 | 421 | 478 |
| Fixed Assets | 164 | 189 | 251 | 303 | 299 |
| Other Non-Current Assets | 69 | 69 | 9 | 8 | 3 |
| Total Current Assets | 24 | 29 | 49 | 109 | 176 |
| Total Assets | 257 | 287 | 309 | 421 | 478 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 13 | 0 | 2 | 5 | 12 |
| Cash Flow from Operating Activities | 17 | 39 | 44 | 60 | 64 |
| Cash Flow from Investing Activities | -78 | -43 | -21 | -52 | -20 |
| Cash Flow from Financing Activities | 47 | 5 | -19 | -1 | -18 |
| Net Cash Inflow / Outflow | -13 | 1 | 3 | 7 | 26 |
| Closing Cash & Cash Equivalent | 0 | 2 | 5 | 12 | 37 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.61 | -0.2 | 2.77 | 6.74 | 10.04 |
| CEPS(Rs) | 1.89 | 2.94 | 6.13 | 10.99 | 14.24 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 8.49 | 8.29 | 11.06 | 17.84 | 27.93 |
| Core EBITDA Margin(%) | 19.68 | 26.32 | 29.76 | 27.93 | 25.98 |
| EBIT Margin(%) | 11.68 | 11.84 | 21 | 21.39 | 21.23 |
| Pre Tax Margin(%) | 4.93 | -1.7 | 12.3 | 15.74 | 16.85 |
| PAT Margin (%) | 3.91 | -1.41 | 8.57 | 11.01 | 12.64 |
| Cash Profit Margin (%) | 12.14 | 13.17 | 17.56 | 17.97 | 17.93 |
| ROA(%) | 1.55 | -0.76 | 6.57 | 12.11 | 14.64 |
| ROE(%) | 7.15 | -3.74 | 30.91 | 46.65 | 43.87 |
| ROCE(%) | 5.4 | 7.53 | 19.3 | 27.07 | 26.88 |
| Receivable days | 42.75 | 36.03 | 42.83 | 55.67 | 67.76 |
| Inventory Days | 8.1 | 6.4 | 4.99 | 3.91 | 3.95 |
| Payable days | 489.53 | 331.95 | 165.15 | 134.8 | 153.39 |
| PER(x) | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.77 | 1.36 | 0.86 | 0.78 | 0.56 |
| EV/Core EBITDA(x) | 8.9 | 5.16 | 2.88 | 2.74 | 2.11 |
| Net Sales Growth(%) | 0 | 43.41 | 56.59 | 75.33 | 29.77 |
| EBIT Growth(%) | 0 | 45.33 | 177.74 | 78.6 | 28.81 |
| PAT Growth(%) | 0 | -151.62 | 1054.12 | 125.45 | 48.92 |
| EPS Growth(%) | 0 | -132.72 | 1495.85 | 143.18 | 48.92 |
| Debt/Equity(x) | 2.96 | 3.4 | 2.57 | 2.21 | 1.44 |
| Current Ratio(x) | 0.57 | 0.48 | 0.9 | 1.13 | 1.77 |
| Quick Ratio(x) | 0.51 | 0.43 | 0.84 | 1.07 | 1.71 |
| Interest Cover(x) | 1.73 | 0.87 | 2.41 | 3.79 | 4.85 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|
| Promoter | 66.33 | 66.33 | 66.44 | 66.54 |
| FII | 4.25 | 5.42 | 2.59 | 3.99 |
| DII | 7.44 | 8.88 | 8.81 | 9.3 |
| Public | 21.97 | 19.37 | 22.15 | 20.16 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|
| Promoter | 5.69 | 5.69 | 5.7 | 5.71 |
| FII | 0.37 | 0.47 | 0.22 | 0.34 |
| DII | 0.64 | 0.76 | 0.76 | 0.8 |
| Public | 1.89 | 1.66 | 1.9 | 1.73 |
| Others | 0 | 0 | 0 | 0 |
| Total | 8.59 | 8.59 | 8.59 | 8.59 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
